SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a selloff in AI infrastructure stocks and concerns that its heavy debt load and costly financing could constrain growth. Traders are split between warnings about dilution and default risk and bullish arguments about AI-compute demand, with Goldmans upgrade and ARKs purchases cited as counterpoints that have not settled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is dominating discussion, with traders citing successive share unlocks and insider selling, a TD Cowen price-target cut, and concerns about OpenAI customer concentration and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are averaging down.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending, with CEO Hock Tans warning that some AI investing resembles gambling adding to concerns. Bears see his comments and AI-credit risks as reasons for continued weakness, while bulls argue demand and Broadcoms fundamentals remain intact and view the decline as a buying opportunity.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention as the S&P 500 rebounds after a tech-led selloff, with investors watching upcoming major-company earnings for signs the recovery can hold. Traders are split between viewing the move as a relief bounce and expecting further downside, amid concerns about AI spending and debt, oil prices, and weak market breadth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center expansion, heavy capital spending and weak free cash flow could strain its credit profile, amid broader doubts about AI infrastructure financing and demand. Many traders remain bearish after the selloff, while others argue Oracles cloud business and backlog can eventually generate returns; speculation about financing arrangements and an upcoming investor event also appears.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. The firm’s products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits, and embedded graphics. The company was founded by Wallace C. Kou in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

SIMO is drawing attention for its growth in AI and data-center storage, particularly boot-drive shipments and MonTitan enterprise SSD controllers, alongside strong results and an upbeat outlook. Many traders see room for further growth, while others point to sharp share-price swings, technical weakness and dilution concerns tied to convertible notes.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths third-quarter earnings beat and raised full-year outlook, supported by improved medical-cost control, are driving attention. Traders are split between viewing the results as evidence of a turnaround and questioning whether the margin improvement will last, while many reacted to the stocks volatile, initially muted response to the report.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a steep AI-infrastructure selloff tied to concerns about neocloud financing, debt, and whether massive data-center spending will earn adequate returns, followed by a volatile rebound. Traders are split between viewing the decline as an oversold buying opportunityoften arguing NBIS is better positioned than CoreWeaveand expecting rallies to fade as sector and market uncertainty persists.

Aventus Network

AVT is drawing attention as traders watch a volatile, thinly traded rebound for a breakout, focusing on trading volume and resistance levels. Aventus Clouds decentralized-compute and enterprise-appchain updates provide a bullish project narrative, but traders remain divided over whether momentum can persist amid low liquidity and selling pressure.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led relief rally after a sharp AI-related selloff has put QQQ in focus, with traders debating whether the volatile rebound signals recovery or is a temporary bounce. Upcoming megacap earnings are a key test, while concerns about AI infrastructure spending and weak market breadth sustain bearish views.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVAPR NewswireNEW YORK, Oct. 3, 2026NEW YORK, Oct. 3, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde...

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.read more...

Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement

(RTTNews) - Lisata Therapeutics (LSTA) has acquired Marea Therapeutics, a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop next-generation medicines for cardioendocrine diseases. The acquisition was structured as a stock-for-stock t...

Lisata Therapeutics Seeks $2 Mln Termination Fee Over Merger Dispute With Kuva, Cuts 72% Workforce

(RTTNews) - Tuesday, Lisata Therapeutics, Inc. (LSTA) announced it has filed a lawsuit against Kuva Labs Inc. and its subsidiary, Kuva Acquisition Corp., in the Delaware Court of Chancery over breach of the merger agreement...

Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics stock fell after hours after updating investors on its pending acquisition and tender offer.read more...

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million.
Lisata Therapeutics (NASDAQ:LSTA)read more...

Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders?

Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 16, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Lisata...

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.read more...

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Lisata Therapeutics Inc

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Lisata and Kuva intend to enter into a definitive purchase agreement before Feb 27.</li><li>Under the deal, Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash.</li><li>Lisata shareholders will also be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.</li></ul>&nbsp;Shares of Lisata Therapeutics, Inc. (LSTA) soared 88% on Wednesday after the company said that it has a buyout offer from privately held Kuva Labs, Inc., valuing the company at up to $6/share.Lisata <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400">said</a> that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. In addition, Lisata shareholders will be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.The transaction has been approved by the board of both companies and Lisata and Kiuva intend to enter into a definitive purchase agreement before Feb 27, Lisata said.The $4 upfront purchase price represents a premium of about 85% from the stock’s closing price on Tuesday.<h2 class="st-heading-2">Lisata’s Pipeline</h2>Lisata’s lead product candidate Certepetide is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.In November 2024, Kuva had licensed Certepetide as a targeting and enhanced delivery agent to be used with its NanoMark platform technology. The NanoMark platform enables selective imaging of solid tumors with high contrast and spatial resolution, facilitating faster and more accurate diagnosis and treatment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LSTA stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that they are not selling their shares for below $8.<stembedurl>https://www.stocktwits.com/iNeedMillions/message/642431338</stembedurl>Another wondered if some other company would make a higher bid for Lisata.<stembedurl>https://www.stocktwits.com/Defen/message/642409160</stembedurl><a href="https://stocktwits.com/symbol/LSTA">LSTA stock</a> has gained 4% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-dismisses-rumors-of-1700-layoffs-at-german-gigafactory-report/cmUDDUFR4fV">Tesla Dismisses Rumors Of 1700 Layoffs At German Gigafactory: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.00
Prev Close	$1.03
Open	$1.03
Dividend Yield	0.00%
50-Day Moving Average	$1.41
Beta	0.60
Avg. Volume	285,323.42
PE Ratio	-0.61

52-Week High	$5.07
52-Week Low	$0.9604
Market Capitalization	$9.28M
EPS (Annual)	-$1.91
Price to Book	1.11
Revenue Per Employee	$8,095.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

LSTA Fundamentals